Stephen E. and Catherine Pappas Center for Neuro-oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Nat Rev Clin Oncol. 2011 Jun;8(6):344-56. doi: 10.1038/nrclinonc.2011.58. Epub 2011 Apr 12.
Brain metastases are a serious obstacle in the treatment of patients with solid tumors and contribute to the morbidity and mortality of these cancers. It is speculated that the frequency of brain metastasis is increasing for several reasons, including improved systemic therapy and survival, and detection of metastases in asymptomatic patients. The lack of preclinical models that recapitulate the clinical setting and the exclusion of patients with brain metastases from most clinical trials have slowed progress. Molecular factors contributing to brain metastases are being elucidated, such as genes involved in cell adhesion, extravasation, metabolism, and cellular signaling. Furthermore, the role of the unique brain microenvironment is beginning to be explored. Although the presence and function of the blood-brain barrier in metastatic tumors is still poorly understood, it is likely that some tumor cells are protected from therapeutics by the blood-tumor barrier, creating a sanctuary site. This Review discusses what is known about the biology of brain metastases, what preclinical models are available to study the disease, and which novel therapeutic strategies are being studied in patients.
脑转移是实体瘤患者治疗的严重障碍,导致这些癌症的发病率和死亡率上升。据推测,脑转移的频率增加有几个原因,包括系统治疗和生存的改善,以及无症状患者转移灶的检测。缺乏能够重现临床环境的临床前模型,以及将脑转移患者排除在大多数临床试验之外,这都阻碍了进展。有助于脑转移的分子因素正在被阐明,例如涉及细胞黏附、渗出、代谢和细胞信号转导的基因。此外,开始探索独特的脑微环境的作用。尽管转移瘤中血脑屏障的存在和功能仍了解甚少,但很可能一些肿瘤细胞受到血-肿瘤屏障的保护,从而形成避难所。这篇综述讨论了已知的脑转移生物学、可用于研究该疾病的临床前模型,以及正在患者中研究的哪些新的治疗策略。